Highlights
KLSE: AHEALTH (7090)       APEX HEALTHCARE BHD MAIN : Health Care
Last Price Today's Change   Day's Range   Trading Volume
3.78   +0.08 (2.16%)  3.69 - 3.81  275,500
Trade this stock and receive a FREE I3investor T-shirt after 5 trades. Find out more.

Financials


Market Cap: 1,796 Million

Market Cap 1,796 Million
NOSH 475 Million

Latest Audited Result:  31-Dec-2019

Latest Audited Result: 31-Dec-2019
Announcement Date 05-Jun-2020
Next Audited Result: 31-Dec-2020
Est. Ann. Date: 05-Jun-2021
Est. Ann. Due Date: 29-Jun-2021

Latest Quarter:  30-Sep-2020 [#3]

Latest Quarter: 30-Sep-2020 [#3]
Announcement Date 19-Nov-2020
Next Quarter: 31-Dec-2020
Est. Ann. Date: 19-Feb-2021
Est. Ann. Due Date: 01-Mar-2021
QoQ | YoY   9.12%  |    0.71%

Annual (Unaudited) ( EPS: 11.10, P/E: 34.04 )

Revenue | NP to SH 688,786  |  52,750
RPS | P/RPS 145.00 Cent  |  2.61
EPS | P/E | EY 11.10 Cent  |  34.04  |  2.94%
DPS | DY | Payout % 3.67 Cent  |  0.97%  |  33.06%
NAPS | P/NAPS 0.89  |  4.23
YoY   -9.95%
NP Margin | ROE 7.66%  |  12.44%
F.Y. | Ann. Date 31-Dec-2019  |  19-Feb-2020

T4Q Result ( EPS: 11.71, P/E: 32.28 )

Revenue | NP to SH 707,786  |  55,631
RPS | P/RPS 149.00 Cent  |  2.54
EPS | P/E | EY 11.71 Cent  |  32.28  |  3.10%
DPS | DY | Payout % 3.68 Cent  |  0.97%  |  31.38%
NAPS | P/NAPS 0.96  |  3.95
QoQ | YoY   0.18%  |    0.15%
NP Margin | ROE 7.86%  |  12.25%
F.Y. | Ann. Date 30-Sep-2020  |  19-Nov-2020

Annualized Result ( EPS: 11.68, P/E: 32.35 )

Revenue | NP to SH 716,202  |  55,502
RPS | P/RPS 150.77 Cent  |  2.51
EPS | P/E | EY 11.68 Cent  |  32.35  |  3.09%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   1.27%  |    7.44%
NP Margin | ROE 7.75%  |  12.22%
F.Y. | Ann. Date 30-Sep-2020  |  19-Nov-2020


Hints :
Click the QoQ or YoY on table to view the QoQ or YoY Financial Result page.

Click here to modify the Visible Columns.

Date Financial Result Financial Ratio Per Share Item Performance Valuation (End of Quarter) Valuation (Ann. Date)
F.Y. Ann. Date Quarter # Revenue PBT NP NP to SH Div Net Worth Div Payout % NP Margin ROE NOSH RPS Adj. RPS EPS Adj. EPS DPS Adj. DPS NAPS Adj. NAPS QoQ YoY EOQ Date EOQ Price EOQ P/RPS EOQ P/EPS EOQ P/NAPS EOQ EY EOQ DY ANN Date ANN Price ANN P/RPS ANN P/EPS ANN P/NAPS ANN EY ANN DY
31-Dec-2020 19-Nov-2020 30-Sep-2020 3 169,116 17,488 14,346 14,223 - 454,102 - % 8.48% 3.13% 473,023 35.75 35.60 3.01 2.99 0.00 0.00 0.9600 0.96   9.12%   0.71% 30-Sep-2020 3.24 9.06 107.75 3.38 0.93% 0.00% 19-Nov-2020 3.60 10.07 119.73 3.75 0.84% 0.00%
31-Dec-2020 26-Aug-2020 30-Jun-2020 2 174,728 16,341 12,930 13,034 8,032 444,145 61.63% 7.40% 2.93% 472,495 36.98 36.78 2.76 2.74 1.70 1.69 0.9400 0.94   -9.30%   -1.44% 30-Jun-2020 2.80 7.57 101.50 2.98 0.99% 0.61% 26-Aug-2020 3.72 10.06 134.85 3.96 0.74% 0.46%
31-Dec-2020 21-May-2020 31-Mar-2020 1 193,308 17,944 14,362 14,370 - 438,661 - % 7.43% 3.28% 471,679 40.98 40.69 3.05 3.03 0.00 0.00 0.9300 0.92   2.61%   26.06% 31-Mar-2020 2.11 5.15 69.26 2.27 1.44% 0.00% 21-May-2020 2.90 7.08 95.19 3.12 1.05% 0.00%
31-Dec-2019 19-Feb-2020 31-Dec-2019 4 170,634 18,484 14,006 14,004 9,426 424,170 67.31% 8.21% 3.30% 471,301 36.20 35.92 2.97 2.95 2.00 1.98 0.9000 0.89   -0.84%   -16.66% 31-Dec-2019 2.24 6.19 75.39 2.49 1.33% 0.89% 19-Feb-2020 2.41 6.66 81.11 2.68 1.23% 0.83%
31-Dec-2019 21-Nov-2019 30-Sep-2019 3 180,653 17,124 14,122 14,123 - 409,992 - % 7.82% 3.44% 471,256 38.33 38.03 3.00 2.97 0.00 0.00 0.8700 0.86   6.80%   -5.20% 30-Sep-2019 2.18 5.69 72.74 2.51 1.37% 0.00% 21-Nov-2019 2.40 6.26 80.08 2.76 1.25% 0.00%
31-Dec-2019 21-Aug-2019 30-Jun-2019 2 159,270 16,183 13,230 13,224 8,008 405,125 60.56% 8.31% 3.26% 471,076 33.81 33.53 2.81 2.78 1.70 1.69 0.8600 0.85   16.01%   -3.47% 28-Jun-2019 2.17 6.42 77.30 2.52 1.29% 0.78% 21-Aug-2019 2.03 6.00 72.31 2.36 1.38% 0.84%
31-Dec-2019 23-May-2019 31-Mar-2019 1 178,229 14,543 11,414 11,399 - 392,099 - % 6.40% 2.91% 117,395 151.82 37.52 9.71 2.40 0.00 0.00 3.3400 0.83   -32.16%   -13.52% 29-Mar-2019 8.87 5.84 91.35 2.66 1.09% 0.00% 23-May-2019 8.60 5.66 88.57 2.57 1.13% 0.00%
31-Dec-2018 28-Feb-2019 31-Dec-2018 4 163,061 16,739 16,803 16,804 8,210 381,202 48.86% 10.30% 4.41% 117,293 139.02 34.33 14.33 3.54 7.00 1.73 3.2500 0.80   12.80%   31.27% 31-Dec-2018 7.80 5.61 54.44 2.40 1.84% 0.90% 28-Feb-2019 8.95 6.44 62.47 2.75 1.60% 0.78%
31-Dec-2018 15-Nov-2018 30-Sep-2018 3 165,253 18,637 14,942 14,897 - 365,595 - % 9.04% 4.07% 117,178 141.03 34.79 12.71 3.14 0.00 0.00 3.1200 0.77   8.75%   32.18% 28-Sep-2018 8.25 5.85 64.89 2.64 1.54% 0.00% 15-Nov-2018 8.10 5.74 63.71 2.60 1.57% 0.00%
31-Dec-2018 16-Aug-2018 30-Jun-2018 2 155,946 17,368 13,701 13,699 7,614 360,809 55.58% 8.79% 3.80% 117,146 133.12 32.83 11.69 2.88 6.50 1.60 3.0800 0.76   3.93%   33.04% 29-Jun-2018 6.79 5.10 58.06 2.20 1.72% 0.96% 16-Aug-2018 7.25 5.45 62.00 2.35 1.61% 0.90%
31-Dec-2018 24-May-2018 31-Mar-2018 1 168,400 16,526 13,221 13,181 - 356,123 - % 7.85% 3.70% 117,146 143.75 35.45 11.25 2.77 0.00 0.00 3.0400 0.75   2.97%   30.62% 30-Mar-2018 5.48 3.81 48.70 1.80 2.05% 0.00% 24-May-2018 5.76 4.01 51.19 1.89 1.95% 0.00%
31-Dec-2017 22-Feb-2018 31-Dec-2017 4 152,585 16,380 12,799 12,801 7,614 343,237 59.48% 8.39% 3.73% 117,146 130.25 32.12 10.93 2.69 6.50 1.60 2.9300 0.72   13.58%   89.48% 29-Dec-2017 5.60 4.30 51.25 1.91 1.95% 1.16% 22-Feb-2018 4.90 3.76 44.84 1.67 2.23% 1.33%
31-Dec-2017 14-Nov-2017 30-Sep-2017 3 157,730 13,302 11,290 11,270 - 330,351 - % 7.16% 3.41% 117,146 134.64 33.20 9.62 2.37 0.00 0.00 2.8200 0.70   9.45%   29.01% 29-Sep-2017 5.10 3.79 53.01 1.81 1.89% 0.00% 14-Nov-2017 5.50 4.08 57.17 1.95 1.75% 0.00%
31-Dec-2017 16-Aug-2017 30-Jun-2017 2 155,297 13,453 10,300 10,297 6,443 325,665 62.57% 6.63% 3.16% 117,146 132.57 32.69 8.79 2.17 5.50 1.36 2.7800 0.69   2.04%   6.72% 30-Jun-2017 4.70 3.55 53.47 1.69 1.87% 1.17% 16-Aug-2017 4.74 3.58 53.93 1.71 1.85% 1.16%
31-Dec-2017 17-May-2017 31-Mar-2017 1 154,652 12,912 10,099 10,091 - 322,151 - % 6.53% 3.13% 117,146 132.02 32.56 8.61 2.12 0.00 0.00 2.7500 0.68   49.36%   2.83% 31-Mar-2017 4.90 3.71 56.88 1.78 1.76% 0.00% 17-May-2017 4.70 3.56 54.56 1.71 1.83% 0.00%
31-Dec-2016 23-Feb-2017 31-Dec-2016 4 144,146 10,079 6,766 6,756 7,028 311,608 104.04% 4.69% 2.17% 117,146 123.05 30.35 5.77 1.42 6.00 1.48 2.6600 0.66   -22.66%   -51.06% 30-Dec-2016 4.30 3.49 74.56 1.62 1.34% 1.40% 23-Feb-2017 4.65 3.78 80.63 1.75 1.24% 1.29%
31-Dec-2016 15-Nov-2016 30-Sep-2016 3 142,960 11,536 8,748 8,736 - 301,065 - % 6.12% 2.90% 117,146 122.04 30.10 7.46 1.84 0.00 0.00 2.5700 0.63   -9.46%   62.35% 30-Sep-2016 4.54 3.72 60.88 1.77 1.64% 0.00% 15-Nov-2016 4.60 3.77 61.68 1.79 1.62% 0.00%
31-Dec-2016 17-Aug-2016 30-Jun-2016 2 146,685 12,313 9,655 9,649 6,443 298,722 66.77% 6.58% 3.23% 117,146 125.22 30.88 8.24 2.03 5.50 1.36 2.5500 0.63   -1.67%   46.13% 30-Jun-2016 3.89 3.11 47.23 1.53 2.12% 1.41% 17-Aug-2016 3.82 3.05 46.38 1.50 2.16% 1.44%
31-Dec-2016 18-May-2016 31-Mar-2016 1 147,478 12,366 9,819 9,813 - 296,379 - % 6.66% 3.31% 117,146 125.89 31.05 8.38 2.07 0.00 0.00 2.5300 0.62   -28.92%   16.19% 31-Mar-2016 3.73 2.96 44.53 1.47 2.25% 0.00% 18-May-2016 3.94 3.13 47.04 1.56 2.13% 0.00%
31-Dec-2015 25-Feb-2016 31-Dec-2015 4 134,248 17,165 13,827 13,806 7,028 288,179 50.91% 10.30% 4.79% 117,146 114.60 28.26 11.79 2.91 6.00 1.48 2.4600 0.61   156.57%   44.64% 31-Dec-2015 3.60 3.14 30.55 1.46 3.27% 1.67% 25-Feb-2016 3.41 2.98 28.93 1.39 3.46% 1.76%
31-Dec-2015 26-Nov-2015 30-Sep-2015 3 128,268 7,721 5,388 5,381 - 274,121 - % 4.20% 1.96% 117,146 109.49 27.00 4.59 1.13 0.00 0.00 2.3400 0.58   -18.51%   -27.38% 30-Sep-2015 3.95 3.61 85.99 1.69 1.16% 0.00% 26-Nov-2015 3.70 3.38 80.55 1.58 1.24% 0.00%
31-Dec-2015 19-Aug-2015 30-Jun-2015 2 124,279 9,076 6,602 6,603 5,857 268,264 88.71% 5.31% 2.46% 117,146 106.09 26.16 5.64 1.39 5.00 1.23 2.2900 0.56   -21.82%   -12.59% 30-Jun-2015 4.02 3.79 71.32 1.76 1.40% 1.24% 19-Aug-2015 3.95 3.72 70.08 1.72 1.43% 1.27%
31-Dec-2015 20-May-2015 31-Mar-2015 1 140,064 11,880 8,446 8,446 - 268,264 - % 6.03% 3.15% 117,146 119.56 29.49 7.21 1.78 0.00 0.00 2.2900 0.56   -11.51%   -10.79% 31-Mar-2015 3.90 3.26 54.09 1.70 1.85% 0.00% 20-May-2015 3.95 3.30 54.79 1.72 1.83% 0.00%
31-Dec-2014 25-Feb-2015 31-Dec-2014 4 123,305 12,671 9,545 9,545 7,028 260,064 73.64% 7.74% 3.67% 117,146 105.26 25.96 8.13 2.01 6.00 1.48 2.2200 0.55   28.81%   24.89% 31-Dec-2014 3.58 3.40 43.94 1.61 2.28% 1.68% 25-Feb-2015 3.64 3.46 44.67 1.64 2.24% 1.65%
31-Dec-2014 18-Nov-2014 30-Sep-2014 3 122,512 10,281 7,410 7,410 - 249,520 - % 6.05% 2.97% 117,146 104.58 25.79 6.30 1.56 0.00 0.00 2.1300 0.53   -1.91%   14.37% 30-Sep-2014 3.86 3.69 61.02 1.81 1.64% 0.00% 18-Nov-2014 3.70 3.54 58.49 1.74 1.71% 0.00%
31-Dec-2014 20-Aug-2014 30-Jun-2014 2 122,493 10,050 7,554 7,554 4,100 246,006 54.28% 6.17% 3.07% 117,146 104.56 25.79 6.42 1.59 3.50 0.86 2.1000 0.52   -20.22%   10.89% 30-Jun-2014 3.80 3.63 58.93 1.81 1.70% 0.92% 20-Aug-2014 3.85 3.68 59.71 1.83 1.67% 0.91%
31-Dec-2014 21-May-2014 31-Mar-2014 1 130,927 12,622 9,468 9,468 - 244,601 - % 7.23% 3.87% 93,717 139.70 27.56 10.07 1.99 0.00 0.00 2.6100 0.51   23.88%   3.90% 31-Mar-2014 4.60 3.29 45.53 1.76 2.20% 0.00% 21-May-2014 4.80 3.44 47.51 1.84 2.10% 0.00%
31-Dec-2013 26-Feb-2014 31-Dec-2013 4 106,210 10,566 7,643 7,643 5,621 235,161 73.55% 7.20% 3.25% 93,690 113.36 22.36 6.50 1.61 6.00 1.18 2.5100 0.50   17.97%   -3.13% 31-Dec-2013 4.50 3.97 55.16 1.79 1.81% 1.33% 26-Feb-2014 4.40 3.88 53.94 1.75 1.85% 1.36%
31-Dec-2013 20-Nov-2013 30-Sep-2013 3 101,680 8,579 6,512 6,479 - 225,030 - % 6.40% 2.88% 93,762 108.44 21.41 6.91 1.36 0.00 0.00 2.4000 0.47   -4.89%   0.61% 30-Sep-2013 4.80 4.43 69.46 2.00 1.44% 0.00% 20-Nov-2013 4.79 4.42 69.32 2.00 1.44% 0.00%
31-Dec-2013 21-Aug-2013 30-Jun-2013 2 104,202 9,273 6,833 6,812 3,748 223,006 55.02% 6.56% 3.05% 93,700 111.21 21.94 7.27 1.43 4.00 0.79 2.3800 0.47   -25.25%   -18.54% 28-Jun-2013 4.49 4.04 61.76 1.89 1.62% 0.89% 21-Aug-2013 4.95 4.45 68.09 2.08 1.47% 0.81%
31-Dec-2013 22-May-2013 31-Mar-2013 1 106,359 12,197 9,134 9,113 - 225,949 - % 8.59% 4.03% 93,755 113.44 22.39 9.72 1.92 0.00 0.00 2.4100 0.48   15.50%   44.19% 29-Mar-2013 4.27 3.76 43.93 1.77 2.28% 0.00% 22-May-2013 4.37 3.85 44.96 1.81 2.22% 0.00%
31-Dec-2012 27-Feb-2013 31-Dec-2012 4 95,993 9,918 7,898 7,890 10,312 216,569 130.71% 8.23% 3.64% 93,752 102.39 20.21 8.42 1.66 11.00 2.17 2.3100 0.46   22.52%   -1.38% 31-Dec-2012 3.68 3.59 43.73 1.59 2.29% 2.99% 27-Feb-2013 4.14 4.04 49.19 1.79 2.03% 2.66%
31-Dec-2012 21-Nov-2012 30-Sep-2012 3 97,807 8,771 6,457 6,440 - 208,104 - % 6.60% 3.09% 93,740 104.34 20.59 6.87 1.36 0.00 0.00 2.2200 0.44   -22.98%   39.79% 28-Sep-2012 3.28 3.14 47.74 1.48 2.09% 0.00% 21-Nov-2012 3.56 3.41 51.82 1.60 1.93% 0.00%
31-Dec-2012 15-Aug-2012 30-Jun-2012 2 100,678 11,333 8,374 8,362 5,624 206,237 67.26% 8.32% 4.05% 93,744 107.40 21.19 8.92 1.76 6.00 1.18 2.2000 0.43   32.31%   28.19% 29-Jun-2012 2.95 2.75 33.07 1.34 3.02% 2.03% 15-Aug-2012 3.11 2.90 34.87 1.41 2.87% 1.93%
31-Dec-2012 23-May-2012 31-Mar-2012 1 104,126 12,327 6,337 6,320 - 205,353 - % 6.09% 3.08% 93,768 111.05 21.92 6.74 1.33 0.00 0.00 2.1900 0.43   -21.00%   -28.78% 30-Mar-2012 2.94 2.65 43.62 1.34 2.29% 0.00% 23-May-2012 2.78 2.50 41.25 1.27 2.42% 0.00%
31-Dec-2011 23-Feb-2012 31-Dec-2011 4 92,330 9,314 7,992 8,000 9,376 198,784 117.21% 8.66% 4.02% 93,766 98.47 19.44 8.54 1.68 10.00 1.97 2.1200 0.42   73.65%   -39.46% 30-Dec-2011 2.74 2.78 32.11 1.29 3.11% 3.65% 23-Feb-2012 2.83 2.87 33.17 1.33 3.01% 3.53%
31-Dec-2011 15-Nov-2011 30-Sep-2011 3 91,867 6,125 4,623 4,607 - 190,085 - % 5.03% 2.42% 93,638 98.11 19.34 4.92 0.97 0.00 0.00 2.0300 0.40   -29.37%   -36.21% 30-Sep-2011 2.60 2.65 52.85 1.28 1.89% 0.00% 15-Nov-2011 2.84 2.89 57.72 1.40 1.73% 0.00%
31-Dec-2011 19-Aug-2011 30-Jun-2011 2 88,983 8,738 6,666 6,523 5,153 189,284 79.01% 7.49% 3.45% 93,705 94.96 18.73 6.96 1.37 5.50 1.08 2.0200 0.40   -26.49%   12.47% 30-Jun-2011 3.05 3.21 43.81 1.51 2.28% 1.80% 19-Aug-2011 2.92 3.07 41.95 1.45 2.38% 1.88%
31-Dec-2011 19-May-2011 31-Mar-2011 1 92,822 11,601 9,115 8,874 - 190,200 - % 9.82% 4.67% 93,694 99.07 19.54 9.47 1.87 0.00 0.00 2.0300 0.40   -32.85%   32.37% 31-Mar-2011 2.90 2.93 30.62 1.43 3.27% 0.00% 19-May-2011 3.00 3.03 31.68 1.48 3.16% 0.00%
31-Dec-2010 24-Feb-2011 31-Dec-2010 4 77,454 19,327 17,691 13,215 8,435 182,760 63.83% 22.84% 7.23% 93,723 82.64 16.31 14.10 2.78 9.00 1.78 1.9500 0.38   82.98%   51.32% 30-Dec-2010 2.59 3.13 18.37 1.33 5.44% 3.47% 24-Feb-2011 2.68 3.24 19.01 1.37 5.26% 3.36%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Analyze this stock with MQ Trader system
  4 people like this.
 
JaBerry Quarter report good. Business growth. Facemask, santinizer, Vit C, Thermometer etc all up.
27/08/2020 9:29 AM
newinvestor17 A report published by Sui Li of PBB stated that there were no suprises in this counter ?

Nabeh KNN MCB, this analyst really knows how to value companies ka ? I am suprised that she didnt find any suprises.

This analyst must be one sei so hai who randomly writes reports based on her mood, just look at her Top Glove reports KNN

Her two bosses never checks her report before publishing ka ?

When a counters TP should be increased, they decrease it and when it should be decreased, they increase it

Really no direction punya amoi and research house
27/08/2020 10:13 AM
enigmatic [control your emotions, discipline your mind] Then write an analysis report which is better than hers to "teach" her. Empty cans make the most noise.
27/08/2020 10:45 AM
chshzhd cheaper than dpharma ..
28/08/2020 10:46 AM
chshzhd Just a myth. Contrary to popular belief, pharmaceutical companies like ApexH are also faced with an uncertain outlook for 2H2020 due to disruptions caused by the pandemic. Weaker consumer sentiment and cautious spending has impacted ApexH’s sales, while the deferment elective medical procedures like orthopaedic surgeries has resulted in lower demand for Straits Apex’s orthopaedic devices. However, during this tough time, ApexH has also completed its cold chain distribution expansion in Singapore, while the expansion in Malaysia is expected to complete in 4QFY20. Given that cold chain distribution is vital for the distribution of vaccine, we are positive on this timely expansion as ApexH would be able to expand into vaccine distribution, be it a Covid-19 vaccine or other vaccines available. However, contrary to market’s belief, we are not expecting immediate benefit arising from any potential vaccine distribution by Apex
Source: PublicInvest Research - 27 Aug 2020
28/08/2020 10:37 PM
LiimInvest Growing & Fundamental
29/08/2020 11:06 PM
mayongzheng https://youtu.be/eIgQAOLapj8
01/09/2020 8:54 PM
Wilfred51a https://news.cgtn.com/news/2020-09-11/Hundreds-of-thousands-have-been-given-Chinese-COVID-19-vaccines-THnoo6BcFG/index.html
12/09/2020 8:29 PM
Benlee88888 https://www.klsescreener.com/v2/news/view/728195
15/09/2020 9:33 PM
Benlee88888 Ini kali lah
15/09/2020 9:33 PM
LiimInvest Next TP over 5.00
15/09/2020 10:41 PM
GorengHealthcare joined to goreng
16/09/2020 10:01 PM
humongainz brother goreng oil la healthcare how can use for goreng aiyaiyai
16/09/2020 10:03 PM
hahasong United States vaccine failed!

The glove unit ESCERAM 0100 is about to fly!
17/09/2020 9:33 AM
Wilfred51a https://www.theedgemarkets.com/article/malaysia-join-covax-vaccine-plan
20/09/2020 7:50 PM
Alfonso jom nasi goreng to the best of the best
25/09/2020 4:29 PM
LiimInvest 吉隆坡1日讯)紧随政府的疫苗采购有进展,驱动大马股市的疫苗概念股在10月第一个交易日纷纷上涨。

发马联合药业受激励

受政府委定为疫苗灌封商的发马(PHARMA,7081,主板医疗保健组)受消息激励,闭市涨38仙(8.8%)至4令吉70仙;联合药业(DPHARMA,7148,主板医疗保健组)起32仙(10.1%)至3令吉48仙,双双跻身10大上涨股。

上述两股皆以接近最高与最高收市,发马成交量176万7600股,联合药业1629万6500股成交。

另一医疗保健股艾柏士保健(AHEALTH,7090,主板医疗保健组)涨9仙至3令吉33仙。

他说,政府通过多种管道和层面去洽谈采购疫苗,并希望越快越好。

“一旦获得卫生部旗下的大马药剂监管局(NPRA)批准,我国尽量在最短的时间内取得或购买冠病疫苗。”
01/10/2020 11:45 PM
50Cents Post removed. Why?
08/10/2020 1:22 AM
NPRA1985 How are the fundamentals of this stock? Good or bad?
25/10/2020 12:22 AM
LiimInvest Very Good fundamental
28/10/2020 12:10 AM
NPRA1985 Sinopharm Vaccine (linked to Kanger) is on track for full approval in November or December

“The most promising of these, developed by Wuhan-based Sinopharm, is already being given to frontline workers in the United Arab Emirates. According to Wu Guizhen, chief biosafety expert at the Chinese Center for Disease Control and Prevention, Sinopharm’s candidate is on track for full approval this month or next.”

https://www.foreignaffairs.com/articles/united-states/2020-11-05/china-winning-vaccine-race?amp=true
07/11/2020 2:31 AM
serendipity89 https://www.malaymail.com/news/malaysia/2020/11/10/buying-covid-19-vaccines-not-so-quick-as-no-infrastructure-yet-dr-noor-hish/1921347

Ahealth management has good business sense. Getting ready cold chain in sg and msia to distribute vaccine.
10/11/2020 10:10 PM
NPRA1985 Efficacy of Sinopharm vaccine is higher than Pfizer vaccine. Sinopharm vaccine showed 100% efficacy while Pfizer vaccine only showed 90% efficacy.

-----------

US drug maker Pfizer said its mRNA vaccine candidate is more than 90 percent effective, while SINOPHARM's inactivated vaccine SHOWED 100 PERCENT efficacy at one case in Mexico, both are promising results and have brought about hope of wider use in the fight against the coronavirus, experts said.

Pfizer's announcement got world's attention and many news outlets reported it with enthusiasm, but Sinopharm's vaccine, which have been used on 56,000 people who have traveled abroad, none of whom became infected, were challenged by many Western media when the data was released.

The different reaction revealed Western media's double standard on vaccines for China and the US, with an aim to politicize the issue, Chinese experts said.

Pfizer's 90 percent was based on phase III clinical trials while Sinopharm's is based on observation after emergency use. Although the former has greater authority academically, the latter is also a control study, Tao further explained, noting that the fact 56,000 people did not get infected could serve as a reference for the vaccine's efficacy.

But a major challenge for mRNA vaccines is the temperature requirement for storage - minus 70C for long-term stability in comparison to 2-8 C for the majority of other types of vaccine, Tao noted, "Storage and transportation will be very expensive."

https://www.globaltimes.cn/content/1206389.shtml
10/11/2020 11:54 PM
NPRA1985 Sinovac vaccine is not related to any companies in Malaysia but just wanted to share anyway.

------------
Brazilian politics, US pressure likely behind Chinese vaccine's suspension: experts

The Chinese Foreign Ministry, the Chinese vaccine producer and a Brazilian institute clarified that Brazilian health regulator's decision to halt trials of a Chinese-produced COVID-19 vaccine in Brazil is NOT RELATED TO THE VACCINE ITSELF, after foreign media said the suspension came following a "severe adverse event."

Chinese experts said politicization of vaccine issues by some Brazilian politicians was likely the reason. They said the vaccine trial issue, which is life-saving work amid the COVID-19 pandemic, should not be influenced by Brazilian political disputes or US pressure.

They stressed that the vaccine is essential to fight the virus, but the suspension without a reasonable excuse could slow down the vaccine-development process.

Wang Wenbin, spokesperson of the ministry, said at a press conference on Tuesday we notice that BUTANTAN INSTITUTE, partner of China's Sinovac Biotech in Brazil, has concluded that the reported "adverse event" that caused Brazil's health regulator on Monday to suspend trials of a Chinese-produced vaccine in Brazil was NOT RELATED TO THE VACCINE produced by Sinovac.

https://www.globaltimes.cn/content/1206393.shtml
11/11/2020 12:07 AM
serendipity89 https://www.theedgemarkets.com/article/apex-healthcare-ready-play-role-vaccine-distribution
11/11/2020 8:48 AM
JaBerry People jump to vaccine company. Do we realise without supply chain and logistics also problem? Apex play important roles and has facilities and temperature control in distributing the vaccine.
11/11/2020 9:52 AM
NPRA1985 China National Pharmaceutical Group Corp (SINOPHARM), a Chinese state-owned enterprise, announced on Wednesday that data from late-stage clinical trials for its Covid-19 vaccine are «BETTER THAN EXPECTED», Reuters reported.

In Morocco, Dr. Abdelhakim Yahyane, a member of the National Scientific Advisory Committee on Vaccination, told Yabiladi earier this week that vaccine trials in the country «have REACHED THE FINAL PHASE».

We are impatiently awaiting the end of this process, which could probably happen BY NEXT WEEK

https://en.yabiladi.com/articles/details/101544/conducted-morocco-among-others-sinopharm-s.html
13/11/2020 9:54 PM
Sinoboy If moderna vaccine is for real, apex health can play a substantial role. Apparently, moderna's vaccine requires storage of only -20C. This is exactly what apex health has, storage facilities that meet this requirement.
Hopefully, such important information is not lost on the public. This counter has great potential
16/11/2020 8:17 PM
Russell Eventually vaccine makers will need to come to Apex Healthcare for its cold chain facility which will be completed in Q4. It just completed it’s cold chain in Singapore. Perfect stock for the recovery trend
16/11/2020 9:13 PM
Sinoboy Hopefully today's uptrend can be maintained...
19/11/2020 6:13 PM
serendipity89 profit seems to have recovered back to pre covid level. next to see is after they completed their cold chain network, whehter they are able to secure distribution contract for the vaccine.
19/11/2020 7:46 PM
LiimInvest Apex Pharma

On 14th September, the Group’s wholly owned manufacturing subsidiary Xepa-Soul Pattinson (M) Sdn Bhd secured renewal of its GMP status with the National Pharmaceutical Regulatory Authority (‘NPRA’) through a scheduled desktop audit. In the quarter, Apex Pharma Marketing Pte Ltd in Singapore increased its cold chain distribution capabilities with the expansion of its current 2-8 degrees C cold room and the acquisition of a -20 degrees C freezer room for pharmaceuticals, vaccines and biologics. Expansion of cold chain distribution capacity in Malaysia is scheduled for completion before the end of the current financial year.
Review of Year To Date Performance versus Corresponding Period Last Year
20/11/2020 12:05 AM
20/11/2020 12:06 AM
DreamGuardian Up 8 sen
20/11/2020 12:06 AM
DreamGuardian Up 2.27%
20/11/2020 12:06 AM
DreamGuardian Okay also la
20/11/2020 12:07 AM
DreamGuardian Boleh juga la
20/11/2020 12:07 AM
DreamGuardian Keep surging
20/11/2020 12:07 AM
DreamGuardian Good luck
20/11/2020 12:07 AM
LiimInvest Tomorrow Fly over 4.50
20/11/2020 12:10 AM
LiimInvest Accumulating more
20/11/2020 12:20 AM
Sinoboy Looking good. Steady she goes, don't falter
20/11/2020 11:52 AM
chshzhd keep..
20/11/2020 4:59 PM
JaBerry Yes keep
23/11/2020 9:22 AM
NPRA1985 Post removed. Why?
23/11/2020 2:00 PM
JaBerry Waiting for vaccines come another distribution income.
27/11/2020 9:36 AM
mrmeow AHEALTH has the cold storage facility and has expanded by acquiring more cold facility and prepared for the covid19 vaccines. Don't foget this real making money one, supplying Msia and Singapore, stable & growing business even before covid, always on an uptrend
27/11/2020 9:41 AM
mrmeow Everyone looking for logistics company that has cold facility for vaccine distribution, yet they forget that this pharmaceutical company does distribution too and has the logistics capable of doing the real work
27/11/2020 12:00 PM
LiimInvest Vaccine-related: Following the approval of Budget 2021, vaccine-related companies will benefit under the Covid-19 fund/fill-and-finish process as well as distribution of vaccines once it is available in the future. Under this segment, SOLUTN, HWGB, BINTAI, DPHARMA, PHARMA, KANGER, -Ahealth, TITIJYA, MAHSING should be under traders radar.

Source: M+ Online
27/11/2020 12:47 PM
serendipity89 ''Apex has been approached by several manufacturers to be the authorised distributor for their upcoming Covid-19 vaccines (work-in-progress). There are many considerations in evaluating these proposals (ie. whether the products will be approved, pricings, efficiencies, requirements, etc) and hence, Apex has not committed to any manufacturer. Instead, the group will likely start off as a wholesaler, where Apex will distribute the Covid-19 vaccines from various manufacturers''

AffinHWang
28/11/2020 1:30 PM